Trials / Unknown
UnknownNCT01878396
Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors
Predictive Value of Circulating Melanoma Cells (CMCs) in Metastatic Melanoma (MM) Patients Treated With Selective Inhibitors of BRAF
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Istituto Oncologico Veneto IRCCS · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study, is to evaluate Circulating Melanoma Cell (CMC) changes in Metastatic Melanoma (MM) patients, undergoing treatment with selective inhibitors of mutated BRAF.
Detailed description
This is an observational prospective pilot study aimed to investigate the association between changes of total and apoptotic CMC count and disease progression in MM patients undergoing treatment with selective inhibitors of mutated B-RAF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anti-B-RAF |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2016-12-01
- Completion
- 2017-12-01
- First posted
- 2013-06-17
- Last updated
- 2016-10-03
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT01878396. Inclusion in this directory is not an endorsement.